Everything below concerns thymus extract. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
==== Pregabalin ==== Pregabalin (Lyrica) produces anxiolytic effect after one week of use comparable to lorazepam, alprazolam, and venlafaxine with more consistent psychic and somatic anxiety reduction. Unlike BZDs, it does not disrupt sleep architecture nor does it cause cognitive or psychomotor impairment.
=== South Korea === The crisis has not had a dramatic impact on the lives of most South Koreans, and energy minister Kim Sung-hwan has said that the country would not experience problems with supply for over a year. However, the Korean Government launched an energy-saving campaign, encouraging its citizens to have brief showers, and limit their use of washing machines, and it has postponed the decommissioning of coal-fired power plants as well as reducing the limit on electricity made from coal.
=== Risk factors === gastrointestinal surgery or other GI procedures electrolyte imbalance (Namely hypokalemia and hypercalcemia) diabetic ketoacidosis (DKA), and other causes of metabolic acidosis hypothyroidism diabetes medications (e.g. opioids or antimuscarinics) severe illness (inflammation with peritonitis) spinal cord injury, those with injury above thoracic vertebra 5 (T5) will have hypomotility problems within the bowel acute intermittent porphyria
=== Lactotrophs === Lactotrophs (also called prolactin cells or mammotrophs) are acidophilic cells of the anterior pituitary that synthesise, store, and secrete prolactin. They develop from the Pit-1 (POU1F1)–dependent lineage, shared with somatotrophs and thyrotrophs. In the normal adult pituitary, lactotrophs constitute approximately 15–25% of anterior pituitary cells; this proportion rises to as high as 50% during pregnancy and lactation owing to estrogen-driven hyperplasia. Lactotrophs are electrically excitable, firing spontaneous action potentials accompanied by calcium transients that sustain continuous exocytosis.
Sources: en.wikipedia.org
Mutations in the GSS gene cause glutathione synthetase deficiency. This gene provides instructions for making the enzyme glutathione synthetase. This enzyme is involved in a process called the gamma-glutamyl cycle, which takes place in most of the body's cells. This cycle is necessary for producing a molecule called glutathione. Glutathione protects cells from damage caused by unstable oxygen-containing molecules, which are byproducts of energy production. Glutathione is called an antioxidant because of its role in protecting cells from the damaging effects of these unstable molecules which are byproducts of energy production. Mutations in the GSS gene prevent cells from making adequate levels of glutathione, leading to the signs and symptoms of glutathione synthetase deficiency. This disorder is inherited in an autosomal recessive pattern, which means the defective gene is located on an autosome, and two copies of the gene - one from each parent - are required to be born with the disorder. The parents of an individual with an autosomal recessive disorder each carry one copy of the defective gene, but usually are not affected by the disorder.
=== In pediatric peanut allergy === Abrocitinib has the ability to decrease T-cell activation and the allergen-specific basophil in the case of peanut allergy. Subsequently, the in vitro allergic responses of peanut allergy are reduced. Abrocitinib may play the role of an immune modulator in oral immunotherapy of peanut or may be administered alone as monotherapy in cases of allergy to certain food.
Severe aortic stenosis with or without symptoms Aortic regurgitation with NYHA functional class III-IV symptoms Mitral stenosis with NYHA functional class II-IV symptoms Mitral regurgitation with NYHA functional class III-IV symptoms Aortic and/or mitral valve disease resulting in severe pulmonary hypertension (pulmonary pressure greater than 75% of systemic pressures) Aortic and/or mitral valve disease with severe LV dysfunction (EF less than 0.40) Mechanical prosthetic valve requiring anticoagulation Marfan syndrome with or without aortic regurgitation
The Cherokee Nation instigated a 10-year language preservation plan that involved developing new fluent speakers of the Cherokee language from childhood on up through school immersion programs, as well as a collaborative community effort to use the language at home. This plan was part of an ambitious goal so that in 50 years, 80% or more of the Cherokee people will be fluent in the language. The Cherokee Preservation Foundation has invested $3 million into opening schools, training teachers, and developing curricula for language education, as well as initiating community gatherings where the language can be used. Formed in 2006, the Kituwah Preservation & Education Program (KPEP) of the Eastern Band of Cherokee Indians, located on the Qualla Boundary in North Carolina, focuses on language immersion programs for children from birth to fifth grade. It is also developing cultural resources for the general public and community language programs to foster use of the Cherokee language among adults. A Cherokee language immersion school in Tahlequah, Oklahoma educates students from pre-school through eighth grade. Several universities offer Cherokee as a second language, including the University of Oklahoma, Northeastern State University, and Western Carolina University. Western Carolina University (WCU) has partnered with the federally recognized Eastern Band of Cherokee Indians (EBCI) to promote and restore the language through the school's Cherokee Studies program. It offers classes in and about the language and culture of the Cherokee Indians.
After much deliberation, we've made the difficult decision to close this location. We are incredibly grateful for the many years of great times, cold beer, hot wings, and unforgettable memories shared here. Thank you to our guests, team members, and community for the support over the years.
Sources: en.wikipedia.org
=== Quantification in disease === Elevation of serum, plasma, or tissue SP and/or its receptor (NK1R) has been associated with many diseases: sickle cell crisis; inflammatory bowel disease; major depression and related disorders; fibromyalgia; rheumatological; and infections such as HIV/AIDS and respiratory syncytial virus, as well as in cancer. When assayed in the human, the observed variability of the SP concentrations are large, and in some cases the assay methodology is questionable. SP concentrations cannot yet be used to diagnose disease clinically or gauge disease severity. It is not yet known whether changes in concentration of SP or density of its receptors is the cause of any given disease, or an effect.
Later on, his statements about doping in the Bundesliga were supported by Per Roentved, Hans Werner Moors, Dieter Schatzscheider, Hans-Josef Kapellmann, Peter Neururer, Benno Möhlmann, Uwe Nester, Peter Geyer (who talked about procedure, quantity and side effects), Jürgen Röber, Jürgen Stumm and Peter Harms (both medics). At Olympique Marseille, doping took place according to Marcel Desailly, Jean-Jacques Eydelie, Chris Waddle, and Tony Cascarino. They told about stimulants taken prior to their big games, which made them more energetic and keen. According to Eydelie, "all [of them] took a series of injections" in the 1993 Champions League final, except Rudi Völler. All this was no surprise for Arsene Wenger, who said everyone in France assumed something like that going on. Additionally, Desailly and Cascarino claimed that Bernard Tapie, the president himself, distributed pills and injections. Author Mondenard also mentioned "injections for everyone". Tapie only admitted that some players took Captagon. Although Juventus won the 1996 Champions League final, the victory was overshowed by of accusations of doping. The Juventus team has been accused of using erythropoietin (EPO) and the matter went to trial in 2004.
This property is what gives DNA its semi-conservative nature where one strand of new DNA is from an original parent strand. Although the structure of DNA showed how inheritance works, it was still not known how DNA influences the behavior of cells. In the following years, scientists tried to understand how DNA controls the process of protein production. It was discovered that the cell uses DNA as a template to create matching messenger RNA, molecules with nucleotides very similar to DNA. The nucleotide sequence of a messenger RNA is used to create an amino acid sequence in protein; this translation between nucleotide sequences and amino acid sequences is known as the genetic code. With the newfound molecular understanding of inheritance came an explosion of research. A notable theory arose from Tomoko Ohta in 1973 with her amendment to the neutral theory of molecular evolution through publishing the nearly neutral theory of molecular evolution. In this theory, Ohta stressed the importance of natural selection and the environment to the rate at which genetic evolution occurs. One important development was chain-termination DNA sequencing in 1977 by Frederick Sanger. This technology allows scientists to read the nucleotide sequence of a DNA molecule. In 1983, Kary Banks Mullis developed the polymerase chain reaction, providing a quick way to isolate and amplify a specific section of DNA from a mixture. The efforts of the Human Genome Project, Department of Energy, NIH, and parallel private efforts by Celera Genomics led to the sequencing of the human genome in 2003.
Many metering pumps are piston-driven. Piston pumps are positive displacement pumps which can be designed to pump at practically constant flow rates (averaged over time) against a wide range of discharge pressure, including high discharge pressures of thousands of psi. Piston-driven metering pumps commonly work as follows: There is a piston (sometimes called plunger), typically cylindrical, which can go in and out of a correspondingly shaped chamber in the pump head. The inlet and outlet lines are joined to the piston chamber. There are two check valves, often ball check valves, attached to the pump head, one at the inlet line and the other at the outlet line. The inlet valve allows flow from the inlet line to the piston chamber, but not in the reverse direction. The outlet valve allows flow from the chamber to the outlet line, but not in reverse. The motor repeatedly moves the piston into and out of the piston chamber, causing the volume of the chamber to repeatedly become smaller and larger. When the piston moves out, a vacuum is created. Low pressure in the chamber causes liquid to enter and fill the chamber through the inlet check valve, but higher pressure at the outlet causes the outlet valve to shut. Then when the piston moves in, it pressurizes the liquid in the chamber. High pressure in the chamber causes the inlet valve to shut and forces the outlet valve to open, forcing liquid out at the outlet. These alternating suction and discharge strokes are repeated over and over to meter the liquid.
TRH is synthesized within parvocellular neurons of the paraventricular nucleus of the hypothalamus. It is translated as a 242-amino acid precursor polypeptide that contains 6 copies of the sequence -Gln-His-Pro-Gly-, with both ends of the sequence flanked by Lys-Arg or Arg-Arg sequences. To produce the mature form, a series of enzymes are required. First, a protease cleaves to the C-terminal side of the flanking Lys-Arg or Arg-Arg. Second, a carboxypeptidase removes the Lys/Arg residues leaving Gly as the C-terminal residue. Then, this Gly is converted into an amide residue by a series of enzymes collectively known as peptidylglycine-alpha-amidating monooxygenase. Concurrently with these processing steps, the N-terminal Gln (glutamine) is converted into pyroglutamate (a cyclic residue). These multiple steps produce 6 copies of the mature TRH molecule per precursor molecule for human TRH (5 for mouse TRH). TRH synthesizing neurons of the paraventricular nucleus project to the medial portion of the external layer of the median eminence. Following secretion at the median eminence, TRH travels to the anterior pituitary via the hypophyseal portal system where it binds to the TRH receptor stimulating the release of thyroid-stimulating hormone from thyrotropes and prolactin from lactotropes. The half-life of TRH in the blood is approximately 6 minutes.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.